{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"0"}],"title":"Very much improved"},{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"8"}],"title":"Much improved"},{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"7"}],"title":"Minimally improved"},{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"50"}],"title":"No change"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}],"title":"Minimally worse"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"Much worse"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"title":"Very much worse"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"72"}],"units":"Participants"}],"title":"Week 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"1"}],"title":"Very much improved"},{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"14"}],"title":"Much improved"},{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"}],"title":"Minimally improved"},{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"35"}],"title":"No change"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"10"}],"title":"Minimally worse"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"title":"Much worse"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"title":"Very much worse"}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Week 8"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"2"}],"title":"Very much improved"},{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"13"}],"title":"Much improved"},{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}],"title":"Minimally improved"},{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"33"}],"title":"No change"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}],"title":"Minimally worse"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}],"title":"Much worse"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"Very much worse"}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"69"}],"units":"Participants"}],"title":"Week 16"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"0"}],"title":"Very much improved"},{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"4"}],"title":"Much improved"},{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"5"}],"title":"Minimally improved"},{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"15"}],"title":"No change"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}],"title":"Minimally worse"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"Much worse"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"Very much worse"}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"title":"Week 28"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"0"}],"title":"Very much improved"},{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"7"}],"title":"Much improved"},{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}],"title":"Minimally improved"},{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"}],"title":"No change"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"title":"Minimally worse"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"Much worse"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"Very much worse"}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Week 40"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"2"}],"title":"Very much improved"},{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"5"}],"title":"Much improved"},{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"1"}],"title":"Minimally improved"},{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"}],"title":"No change"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}],"title":"Minimally worse"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"Much worse"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"Very much worse"}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"title":"Week 52"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"1"}],"title":"Very much improved"},{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"1"}],"title":"Much improved"},{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"}],"title":"Minimally improved"},{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"0"}],"title":"No change"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"title":"Minimally worse"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"Much worse"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"Very much worse"}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"Week 66"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"0"}],"title":"Very much improved"},{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"0"}],"title":"Much improved"},{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"0"}],"title":"Minimally improved"},{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"0"}],"title":"No change"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"title":"Minimally worse"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"title":"Much worse"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"title":"Very much worse"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Week 80"}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"75"}],"units":"Participants"}],"description":"The Patient Global Impression of Change (PGIC) is comprised of a single question intended to measure a patient's perspective of improvement or deterioration over time relative to treatment. The PGIC uses a seven-point scale where one (1) equals very much improved and seven (7) equals very much worse.","groups":[{"description":"Ruxolitinib at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid","id":"OG000","title":"Ruxolitinib"},{"description":"Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib","id":"OG001","title":"Best Available Therapy (BAT)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full Analysis Set (FAS) included all participants to whom study treatment was assigned by randomization and had valid measurements for the outcome measure. Data after crossover for participants randomized to BAT are reported as separate outcome measure.","reportingStatus":"POSTED","timeFrame":"Week 4, 8, 16, 28, 40, 52 and 80","title":"Patient Global Impression of Change (PGIC)","type":"SECONDARY","unitOfMeasure":"Participants"}